Casgevy is an English word starting with the letter C. With 3 example sentences you'll see exactly how it works in context.
Casgevy in a sentence
Context around Casgevy
- Average sentence length in these examples: 24 words
- Position in the sentence: 1 start, 2 middle, 0 end
- Sentence types: 3 statements, 0 questions, 0 exclamations
Corpus analysis for Casgevy
- In this selection, "casgevy" usually appears in the middle of the sentence. The average example has 24 words, and this corpus slice is mostly made up of statements.
- Around the word, new and treatment stand out and add context to how "casgevy" is used.
- Recognizable usage signals include destination for casgevy is the and studies of casgevy in patients. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "casgevy" sits close to words such as aadujeevitham, aani and aarne, which helps place it inside the broader word index.
Example types with casgevy
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
Completed enrollment in two global Phase 3 studies of CASGEVY in patients 5 to 11 years of age with SCD or TDT. (22 words)
As Stuart, our Chief Commercial and Chief Operating Officer always says, the destination for CASGEVY is the same as we see for cystic fibrosis. (24 words)
The new Casgevy treatment alters patients’ genes to produce healthy round red blood cells, rather than the crescent- or sickle-shaped cells that cause the disease. (26 words)
The new Casgevy treatment alters patients’ genes to produce healthy round red blood cells, rather than the crescent- or sickle-shaped cells that cause the disease. (26 words)
As Stuart, our Chief Commercial and Chief Operating Officer always says, the destination for CASGEVY is the same as we see for cystic fibrosis. (24 words)
Completed enrollment in two global Phase 3 studies of CASGEVY in patients 5 to 11 years of age with SCD or TDT. (22 words)
Example sentences (3)
As Stuart, our Chief Commercial and Chief Operating Officer always says, the destination for CASGEVY is the same as we see for cystic fibrosis.
Completed enrollment in two global Phase 3 studies of CASGEVY in patients 5 to 11 years of age with SCD or TDT.
The new Casgevy treatment alters patients’ genes to produce healthy round red blood cells, rather than the crescent- or sickle-shaped cells that cause the disease.